Cerebras Systems, a pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI work.

Genesis Therapeutics and Eli Lilly entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.

PharmaLive talked to Gerald Martinetz at Mindbreeze regarding how data is transforming R&D in the metaverse.

The U.S. Food and Drug Administration approved BioXcel Therapeutics Inc.’s IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Global health innovation company Real Chemistry announced the acquisition of conversationHEALTH, a conversational artificial intelligence (AI) platform for the health care and life sciences industry.

Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors. 

Verantos – a market leader in high-validity real-world evidence generation – announced that along with its research partners, the company accomplished a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH).

EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, announced its technology-enabled platform ACTICS by EVERSANA™ was named a 2022 Artificial Intelligence (AI) Award winner.


IQVIA announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity and increased ROI.

Dubbed Cambridge Crossing, Sanofi’s new U.S. facilities set to open during May 2022 will hold the tools to develop innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among many other key modalities.